Performance of two prognostic scores that incorporate genetic information to predict long‐term outcomes following resection of colorectal cancer liver metastases: An external validation of the MD Anderson and JHH‐MSK scores
Journal of hepato-biliary-pancreatic sciences, 2021-07, Vol.28 (7), p.581-592
Two novel clinical risk scores (CRS) that incorporate KRAS mutation status were developed: modified CRS (mCRS) and GAME score. However, they have not been tested in large national and international cohorts. The aim of this study was to validate the prognostic discrimination utility and determine the clinical usefulness of the two novel CRS.
Patients undergoing hepatectomy for CRLM (2000‐2018) in 10 centers were included. The discriminatory abilities of mCRS, GAME, and Fong CRS were evaluated using Harrell's C‐index and Akaike's Information Criterion.
In the entire cohort, the C‐index of the GAME score (0.61) was significantly higher than those of Fong score (0.57) and mCRS (0.54), while the C‐Index of mCRS was significantly lower than that of Fong score. When we compared the models in the various geographical regions, the C‐index of GAME score was significantly higher than that of mCRS in North America, Europe, and South America. The AIC of Fong score, mCRS, and GAME score were 14 405, 14 447, and 14 319, respectively.
In conclusion, using the largest and most heterogenous population of CRLM patients with known KRAS status, this independent, external validation demonstrated that the GAME score outperforms both the traditional Fong score and mCRS.
Sasaki and colleagues conducted an international multi‐center retrospective study to compare two novel clinical risk scores that incorporate KRAS mutation status (mCRS and GAME score) with the Fong score as the gold standard in prognostic utility. In this independent external validation, the GAME score outperformed both the Fong score and mCRS.